Literature DB >> 7507901

Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis.

R E Garner1, J E Domer.   

Abstract

Candida albicans mannoprotein (MAN) administered to mice before or during immunization with viable C. albicans downregulates MAN-specific delayed hypersensitivity. In the experiments reported here we determined the effect of MAN downregulation on protective immunity in minimally immunized mice, i.e., mice exposed to C. albicans either intradermally or intragastrically, and in maximally immunized mice, i.e., mice immunized by a combination of intradermal and intragastric exposure, in experimental systemic candidiasis. MAN suppression did not induce statistically significant alterations in the protective responses in experimental candidiasis, although 8 of 12 groups of mice treated with MAN had fewer CFU of C. albicans in their kidneys than their non-MAN-treated counterparts. The results emphasize the lack of correlation of delayed hypersensitivity with protection in candidiasis and suggest that MAN may contain epitopes involved in the protective response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507901      PMCID: PMC186170          DOI: 10.1128/iai.62.2.738-741.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.

Authors:  J E Domer; R E Garner; R N Befidi-Mengue
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

2.  Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice.

Authors:  E Balish; H Filutowicz; T D Oberley
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

3.  Murine candidiasis: cell-mediated immune responses correlate directly with susceptibility and resistance to infection.

Authors:  R B Ashman
Journal:  Immunol Cell Biol       Date:  1990-02       Impact factor: 5.126

4.  Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells.

Authors:  R E Garner; A M Childress; L G Human; J E Domer
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

5.  Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line.

Authors:  T G Sieck; M A Moors; H R Buckley; K J Blank
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

6.  Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans.

Authors:  J E Domer; R F Hector
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  Acquired immunity to systemic candidiasis in immunodeficient mice.

Authors:  M T Cantorna; E Balish
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

8.  Nonspecific and Candida-specific immune responses in mice suppressed by chronic administration of anti-mu.

Authors:  U Kuruganti; L A Henderson; R E Garner; R Asofsky; P J Baker; J E Domer
Journal:  J Leukoc Biol       Date:  1988-11       Impact factor: 4.962

9.  In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon.

Authors:  R E Garner; U Kuruganti; C W Czarniecki; H H Chiu; J E Domer
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

10.  T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

View more
  9 in total

1.  Cytokine involvement in immunomodulatory activity affected by Candida albicans mannan.

Authors:  Y Wang; S P Li; S A Moser; K L Bost; J E Domer
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

2.  Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A.

Authors:  S P Li; S I Lee; J E Domer
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

3.  A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.

Authors:  A Mencacci; A Torosantucci; R Spaccapelo; L Romani; F Bistoni; A Cassone
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

4.  Candida albicans primes TLR cytokine responses through a Dectin-1/Raf-1-mediated pathway.

Authors:  Daniela C Ifrim; Leo A B Joosten; Bart-Jan Kullberg; Liesbeth Jacobs; Trees Jansen; David L Williams; Neil A R Gow; Jos W M van der Meer; Mihai G Netea; Jessica Quintin
Journal:  J Immunol       Date:  2013-03-08       Impact factor: 5.422

5.  Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Authors:  P L Fidel; M E Lynch; D H Conaway; L Tait; J D Sobel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

Review 6.  Production and function of cytokines in natural and acquired immunity to Candida albicans infection.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Microbiol Rev       Date:  1995-12

7.  Antibody response that protects against disseminated candidiasis.

Authors:  Y Han; J E Cutler
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

8.  Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

9.  Candida albicans-derived mannoproteins activate NF-κB in reporter cells expressing TLR4, MD2 and CD14.

Authors:  Traci Ness; Mahmud Abdallah; Jaime Adams; Claudia Alvarado; Edwin Gunn; Brittany House; John Lamb; Jack Macguire; Emily Norris; Rebekah Robinson; Morgan Sapp; Jill Sharma; Ronald Garner
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.